Curis Inc (CRIS)

[Desert dweller]

This story is from the street.com and I wonder why they only mentioned the 1 abstract? I would think positive data on the lung cancer abstract or the pancreatic abstract could provide as much or more of a pop to Curis than the one mentioned. Although Wednesday could provide good news, as the article below states, we may have to wait until the actual presentations to find out the juicy details.

http://www.thestreet.com/story/11114682/1/cancer-stocks-on-tap-asco-abstract-preview.html

BOSTON (TheStreet) -- Biotech investors take note: On Weds. May 18, the American Society of Clinical Oncology (ASCO) will be posting online the full content of cancer drug research abstracts to be presented next month at its closely watched annual meeting in Chicago.

The ASCO research abstracts will be posted on the medical society's web site starting at 6 p.m. EDT -- free for everyone to browse and download. The ASCO annual meeting -- the most important cancer drug research meeting every year -- runs June 3-7.

Biotech traders start focusing on "ASCO stocks" early in the year, well before the release of research abstracts.

A research abstract is simply a summary of clinical data to be presented at a medical conference. The abstract typically includes a brief description of the clinical study, the types of patients enrolled and sometimes, a brief summary of the study results, including efficacy and safety data.

Research abstracts can be flinty on the important details investors want to know. Think of a research abstract as a placeholder a company uses to reserve a spot at a medical meeting. A cancer research meeting like ASCO is a very hot ticket, so companies vie for presentation slots well in advance. Often, that means the cancer drug data companies want to present isn't ready or fully analyzed yet. ASCO abstracts, therefore, often summarize the study but put off disclosing the important details (like if the drug being studied works and is safe) until the actual data presentation at the meeting.
To make it easier for investors to search ASCO's annual meeting web site next Wednesday, I put together a list of abstracts most interesting to Wall Street, arranged alphabetically by drug sponsor.

Roche and Curis(CRIS_)

Abstract No. TPS173

Abstract title: A randomized, double-blind placebo-controlled phase II study of FOLFOX with or without GDC-0449 (vismodegib) in patients with advanced gastric and gastroesophageal junction carcinoma (NCI 8376).